1. Home
  2. BGX vs RANI Comparison

BGX vs RANI Comparison

Compare BGX & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone Long Short Credit Income Fund

BGX

Blackstone Long Short Credit Income Fund

HOLD

Current Price

$11.82

Market Cap

151.0M

Sector

Finance

ML Signal

HOLD

Logo Rani Therapeutics Holdings Inc.

RANI

Rani Therapeutics Holdings Inc.

HOLD

Current Price

$1.48

Market Cap

134.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGX
RANI
Founded
2010
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.0M
134.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BGX
RANI
Price
$11.82
$1.48
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.67
AVG Volume (30 Days)
67.9K
2.8M
Earning Date
01-01-0001
11-06-2025
Dividend Yield
10.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,200,000.00
Revenue This Year
N/A
$414.59
Revenue Next Year
N/A
$30.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.69
$0.39
52 Week High
$12.44
$3.87

Technical Indicators

Market Signals
Indicator
BGX
RANI
Relative Strength Index (RSI) 50.31 44.28
Support Level $11.76 $1.52
Resistance Level $11.90 $1.67
Average True Range (ATR) 0.11 0.14
MACD 0.01 -0.03
Stochastic Oscillator 65.22 28.57

Price Performance

Historical Comparison
BGX
RANI

About BGX Blackstone Long Short Credit Income Fund

Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. It seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.

About RANI Rani Therapeutics Holdings Inc.

Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.

Share on Social Networks: